Cargando…

Pegaptanib Sodium versus Pegaptanib Sodium Combined with Macular Laser Photocoagulation or Laser Alone for Diabetic Macular Edema

Purpose. To report the outcomes after primary intravitreal pegaptanib sodium in patients with diabetic macular edema (DME). Methods. We conduced a retrospective analysis of eyes with DME treated with primary intravitreal pegaptanib sodium (Macugen) (intravitreal pegaptanib group). The results were c...

Descripción completa

Detalles Bibliográficos
Autores principales: Querques, G., Bux, A. V., Fusco, A. R., Iaculli, C., Delle Noci, N.
Formato: Texto
Lenguaje:English
Publicado: Hindawi Publishing Corporation 2009
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2836737/
https://www.ncbi.nlm.nih.gov/pubmed/20339449
http://dx.doi.org/10.1155/2009/672178
_version_ 1782178731438112768
author Querques, G.
Bux, A. V.
Fusco, A. R.
Iaculli, C.
Delle Noci, N.
author_facet Querques, G.
Bux, A. V.
Fusco, A. R.
Iaculli, C.
Delle Noci, N.
author_sort Querques, G.
collection PubMed
description Purpose. To report the outcomes after primary intravitreal pegaptanib sodium in patients with diabetic macular edema (DME). Methods. We conduced a retrospective analysis of eyes with DME treated with primary intravitreal pegaptanib sodium (Macugen) (intravitreal pegaptanib group). The results were compared with the ones of eyes treated with intravitreal pegaptanib sodium associated with macular laser photocoagulation (combined treatment group), and the ones of eyes treated with primary macular laser photocoagulation (macular laser photocoagulation group). Results. For the intravitreal pegaptanib group (13 eyes), we found significant changes in mean best-corrected visual acuity (BCVA) and reductions in mean central macular thickness (CMT) at the last follow-up visit (P = .0014 and P = .0001). For the macular laser photocoagulation group (15 eyes), we found no statistically significant changes in mean BCVA and CMT at the last follow-up visit (P > .05). For the combined treatment group (12 eyes), we found no significant changes in mean BCVA at the last follow-up visit (P > .05) despite significant reductions in mean CMT (P = .0188). Conclusion. Intravitreal pegaptanib treatment alone may be superior to macular laser photocoagulation alone and to combined intravitreal pegaptanib treatment associated with macular laser photocoagulation in patients with DME.
format Text
id pubmed-2836737
institution National Center for Biotechnology Information
language English
publishDate 2009
publisher Hindawi Publishing Corporation
record_format MEDLINE/PubMed
spelling pubmed-28367372010-03-25 Pegaptanib Sodium versus Pegaptanib Sodium Combined with Macular Laser Photocoagulation or Laser Alone for Diabetic Macular Edema Querques, G. Bux, A. V. Fusco, A. R. Iaculli, C. Delle Noci, N. J Ophthalmol Clinical Study Purpose. To report the outcomes after primary intravitreal pegaptanib sodium in patients with diabetic macular edema (DME). Methods. We conduced a retrospective analysis of eyes with DME treated with primary intravitreal pegaptanib sodium (Macugen) (intravitreal pegaptanib group). The results were compared with the ones of eyes treated with intravitreal pegaptanib sodium associated with macular laser photocoagulation (combined treatment group), and the ones of eyes treated with primary macular laser photocoagulation (macular laser photocoagulation group). Results. For the intravitreal pegaptanib group (13 eyes), we found significant changes in mean best-corrected visual acuity (BCVA) and reductions in mean central macular thickness (CMT) at the last follow-up visit (P = .0014 and P = .0001). For the macular laser photocoagulation group (15 eyes), we found no statistically significant changes in mean BCVA and CMT at the last follow-up visit (P > .05). For the combined treatment group (12 eyes), we found no significant changes in mean BCVA at the last follow-up visit (P > .05) despite significant reductions in mean CMT (P = .0188). Conclusion. Intravitreal pegaptanib treatment alone may be superior to macular laser photocoagulation alone and to combined intravitreal pegaptanib treatment associated with macular laser photocoagulation in patients with DME. Hindawi Publishing Corporation 2009 2010-03-09 /pmc/articles/PMC2836737/ /pubmed/20339449 http://dx.doi.org/10.1155/2009/672178 Text en https://creativecommons.org/licenses/by/3.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Clinical Study
Querques, G.
Bux, A. V.
Fusco, A. R.
Iaculli, C.
Delle Noci, N.
Pegaptanib Sodium versus Pegaptanib Sodium Combined with Macular Laser Photocoagulation or Laser Alone for Diabetic Macular Edema
title Pegaptanib Sodium versus Pegaptanib Sodium Combined with Macular Laser Photocoagulation or Laser Alone for Diabetic Macular Edema
title_full Pegaptanib Sodium versus Pegaptanib Sodium Combined with Macular Laser Photocoagulation or Laser Alone for Diabetic Macular Edema
title_fullStr Pegaptanib Sodium versus Pegaptanib Sodium Combined with Macular Laser Photocoagulation or Laser Alone for Diabetic Macular Edema
title_full_unstemmed Pegaptanib Sodium versus Pegaptanib Sodium Combined with Macular Laser Photocoagulation or Laser Alone for Diabetic Macular Edema
title_short Pegaptanib Sodium versus Pegaptanib Sodium Combined with Macular Laser Photocoagulation or Laser Alone for Diabetic Macular Edema
title_sort pegaptanib sodium versus pegaptanib sodium combined with macular laser photocoagulation or laser alone for diabetic macular edema
topic Clinical Study
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2836737/
https://www.ncbi.nlm.nih.gov/pubmed/20339449
http://dx.doi.org/10.1155/2009/672178
work_keys_str_mv AT querquesg pegaptanibsodiumversuspegaptanibsodiumcombinedwithmacularlaserphotocoagulationorlaseralonefordiabeticmacularedema
AT buxav pegaptanibsodiumversuspegaptanibsodiumcombinedwithmacularlaserphotocoagulationorlaseralonefordiabeticmacularedema
AT fuscoar pegaptanibsodiumversuspegaptanibsodiumcombinedwithmacularlaserphotocoagulationorlaseralonefordiabeticmacularedema
AT iacullic pegaptanibsodiumversuspegaptanibsodiumcombinedwithmacularlaserphotocoagulationorlaseralonefordiabeticmacularedema
AT dellenocin pegaptanibsodiumversuspegaptanibsodiumcombinedwithmacularlaserphotocoagulationorlaseralonefordiabeticmacularedema